RecruitingNCT06631157
Essential Pro Study ( rEPIC04E-HK )
Essential Pro Post-Market Clinical Follow-up Study
Sponsor
Fundación EPIC
Enrollment
100 participants
Start Date
May 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patient treated with Essential Pro according to routine hospital practice and following instructions for use
- Informed consent signed
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEEssential pro
Patients in whom treatment with (Essential Pro) has been attempted
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06631157
Related Trials
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
NCT067368998 locations
Coroflex® ISAR NEO PMCF Study
NCT0569873222 locations
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
NCT067102101 location
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT0542737043 locations
Scaffold in Emilia Romagna and in the MAGIC Network
NCT0332796117 locations